Related references
Note: Only part of the references are listed.Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
Benjamin Chuah et al.
CANCER SCIENCE (2011)
Multicenter Phase II Study of Gemcitabine and S-1 Combination Therapy (GS Therapy) in Patients With Metastatic Pancreatic Cancer
Hideki Ueno et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler et al.
LANCET ONCOLOGY (2011)
CHEMOTHERAPY Metastatic pancreatic cancer-is FOLFIRINOX the new standard?
M. Wasif Saif et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
Chigusa Morizane et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
S-1: a promising new oral fluoropyrimidine derivative
Muhammad Wasif Saif et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Development History and Concept of an Oral Anticancer Agent S-1 (TS-1((R))): Its Clinical Usefulness and Future Vistas
Tetsuhiko Shirasaka
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Potential regional differences for the tolerability profiles of fluoropyrimidines
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A late phase II study of S-1 for metastatic pancreatic cancer
Takuji Okusaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer:: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
Volker Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
An early phase II study of S-1 in patients with metastatic pancreatic cancer
H Ueno et al.
ONCOLOGY (2005)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
